Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors

Investigational New Drugs

Volumn 25, Issue 3, 2007, Pages 227-235

  Kuppens, I E L M ^a,f   Witteveen, P O ^b   Schot, M ^a   Schuessler, V M ^c   Daehling, A ^c   Beijnen, J H ^d,e   Voest, E E ^b   Schellens, J H M ^d,e  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Baxter Deutschland GmbH   (Germany)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

D 24851; Dose escalation; Food effect; Indibulin; Oral; Phase I

Indexed keywords

ANTINEOPLASTIC AGENT; D 24851; INDIBULIN; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BRONCHUS CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; COUGHING; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DYSPEPSIA; FACE EDEMA; FATIGUE; FEMALE; HUMAN; KIDNEY CANCER; KIDNEY CONCENTRATING CAPACITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NEUROPATHY; OROPHARYNX CARCINOMA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; SALIVATION; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; SPUTUM; STOMATITIS; THRUSH;

ACETAMIDES; ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; INDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NETHERLANDS; PILOT PROJECTS; POSTPRANDIAL PERIOD; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 34248633351     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9027-2     Document Type: Article

References (14)

1. Jordan MA (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti-Canc Agents 2:1-17
2. Stokvis E, Nan-Offeringa LG, Ouwehand M, Tibben MM, Rosing H, Schnaars Y, Grigat M, Romeis P, Schellens JH, Beijnen JH (2004) Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 18:1465-1471
3. Baxter (2003) Investigator's Brochure D-24851. 4 February
4. Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17:1061-1070
5. Hussain M, Wozniak AJ, Edelstein MB (1993) Neurotoxicity of antineoplastic agents. Crit Rev Oncol Hematol 14:61-75
6. Hilkens PH, Verweij J, Vecht CJ, Stoter G, Van Den Bent MJ (1997) Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 8:187-190
7. Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM (1996) Motor neuropathy due to docetaxel and paclitaxel. Neurology 47:115-118
8. Windebank AJ (1999) Chemotherapeutic neuropathy. Curr Opin Neurol 12:565-571
9. Bacher G, Nickel B, Emig P, Vanhoefer U, Seeber S, Shandra A, Klenner T, Beckers T (2001) D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 61:392-399
10. Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48:353-374
11. Schiller JH (1998) Role of taxanes in lung-cancer chemotherapy. Cancer Invest 16:471-477
12. Wood KW, Cornwell WD, Jackson JR (2001) Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 1:370-377
13. Food-Effect Bioavailability and Fed Bioequivalence Studies, Study Desing DAaL (2001) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER): Guidance for Industry. Draft October
14. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2002) Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies. http://www.fda.gov/ cder/guidance/5194fnl.pdf